Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement, whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
148 USD | -1.27% | -4.22% | -22.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.68% | 18.96B | |
+28.30% | 48.16B | |
-0.16% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.02% | 25.59B | |
+8.63% | 12.92B | |
+29.93% | 12.03B | |
-1.79% | 11.77B | |
+21.84% | 11.73B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023